GlassScriptPhysician profile
Mary B Kirby
NPI 1104872316
$2,216.92
in general payments reported to CMS, 2019-2025
27 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $149 · 2021: $242 · 2022: $232 · 2023: $417 · 2024: $402 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $252.31 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $243.19 | 2019-2021 | |
| Axsome Therapeutics, INC. | $236.45 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $231.47 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $183.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $158.98 | 2019-2025 | Airsupra |
| Abbvie INC. | $147.71 | 2023-2024 | |
| Shield Therapeutics INC | $123.56 | 2023-2024 | Accrufer |
| Pfizer INC. | $84.33 | 2019-2025 | |
| Lilly USA, LLC | $80.99 | 2019-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.30 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $64.96 | 2019-2022 | |
| Boston Scientific Corporation | $56.25 | 2019-2025 | Intracept |
| Amarin Pharma, INC. | $30.68 | 2020-2021 | |
| Baxter Healthcare | $29.26 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $27.90 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $27.72 | 2021-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $24.78 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $22.84 | 2019-2022 | |
| Tolmar, INC. | $20.39 | 2025 | Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2024 | |
| Medtronic, INC. | $17.61 | 2023 | Intellis Adaptivestim |
| Allergan, INC. | $15.18 | 2019 | |
| Esperion Therapeutics, INC. | $14.88 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.56 | 2021 | |
| Hikma Pharmaceuticals USA | $12.75 | 2019 | |
| Abbott Laboratories | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Kirby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.